Clinical Significance of Serum Angiocidin Levels in Hepatocellular Carcinoma

Overview

Journal Cancer Lett

Specialty Oncology

Date 2006 Dec 26

PMID 17188426

Citations 6

Authors

Yamini Sabherwal

Vicki L Rothman

Ronnie T P Poon

George P Tuszynski

Affiliations

Soon will be listed here.

Abstract

Angiocidin, a tumor-secreted protein, was measured in serum of 27 healthy volunteers and 33 hepatocellular carcinoma (HCC) patients. Healthy controls either hepatitis B surface antigen (HBsAg) positive or negative showed undetectable levels. Patients had levels of angiocidin ranging from 15.09 to 195.73 pg/ml. Patients with stages III-IV had higher levels of angiocidin (97+/-13 pg/ml, n=17) compared to those with stages I-II (63+/-37 pg/ml, n=16), p<0.043. Patients with microsatellite tumor nodules had higher average levels (98+/-55 pg/ml, n=17) compared to those without microsatellite nodules (51+/-27 pg/ml, n=20), p<0.032. Our studies suggest that angiocidin predicts advanced stage and intra-hepatic metastasis.

Citing Articles

Oncofetal MCB1 Is a Functional Biomarker for HCC Personalized Therapy.

Xiang D, Liu J, Wang Y, Hu D, Zhang C, Zeng T Adv Sci (Weinh). 2024; 11(45):e2401228.

PMID: 39402741 PMC: 11615823. DOI: 10.1002/advs.202401228.

Reduction of angiocidin contributes to decreased HepG2 cell proliferation.

Guan X, Guan X, Feng K, Jian R, Tian D, Tong H Afr Health Sci. 2013; 13(3):560-4.

PMID: 24250289 PMC: 3824429. DOI: 10.4314/ahs.v13i3.5.

The interaction of angiocidin with tissue transglutaminase.

LHeureux D, Rothman V, Tuszynski G Exp Mol Pathol. 2009; 88(1):15-25.

PMID: 19931242 PMC: 2815215. DOI: 10.1016/j.yexmp.2009.11.001.

Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: exploring the functional significance in tumor cell invasion.

John A, Hu X, Rothman V, Tuszynski G Exp Mol Pathol. 2009; 87(3):184-8.

PMID: 19747478 PMC: 2783349. DOI: 10.1016/j.yexmp.2009.09.002.

The novel angiogenic inhibitor, angiocidin, induces differentiation of monocytes to macrophages.

Gaurnier-Hausser A, Rothman V, Dimitrov S, Tuszynski G Cancer Res. 2008; 68(14):5905-14.

PMID: 18632645 PMC: 2512970. DOI: 10.1158/0008-5472.CAN-07-6179.

References

Varela M, Sala M, Llovet J, Bruix J . Treatment of hepatocellular carcinoma: is there an optimal strategy?. Cancer Treat Rev. 2003; 29(2):99-104. DOI: 10.1016/s0305-7372(02)00123-8. View

Sabherwal Y, Rothman V, Dimitrov S, LHeureux D, Marcinkiewicz C, Sharma M . Integrin alpha2beta1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein. Exp Cell Res. 2006; 312(13):2443-53. DOI: 10.1016/j.yexcr.2006.04.009. View

Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J . Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002; 95(9):1931-7. DOI: 10.1002/cncr.10892. View

Tuszynski G, Nicosia R . Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma. Lab Invest. 1994; 70(2):228-33. View

Sabherwal Y, Rothman V, Poon R, Tuszynski G . Clinical significance of serum angiocidin levels in hepatocellular carcinoma. Cancer Lett. 2006; 251(1):28-35. PMC: 1955767. DOI: 10.1016/j.canlet.2006.10.023. View

Zhou J, Rothman V, Sargiannidou I, Dimitrov S, Qiu C, Smith E . Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1. J Cell Biochem. 2004; 92(1):125-46. DOI: 10.1002/jcb.20076. View

Tahara T, Usuki K, Sato H, Ohashi H, Morita H, Tsumura H . A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br J Haematol. 1996; 93(4):783-8. DOI: 10.1046/j.1365-2141.1996.d01-1741.x. View

Young P, Deveraux Q, Beal R, Pickart C, Rechsteiner M . Characterization of two polyubiquitin binding sites in the 26 S protease subunit 5a. J Biol Chem. 1998; 273(10):5461-7. DOI: 10.1074/jbc.273.10.5461. View

Tuszynski G, Rothman V, Papale M, Hamilton B, Eyal J . Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain. J Cell Biol. 1993; 120(2):513-21. PMC: 2119506. DOI: 10.1083/jcb.120.2.513. View

10.

OReilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2):277-85. DOI: 10.1016/s0092-8674(00)81848-6. View

11.

Zhou L, Liu J, Luo F . Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 2006; 12(8):1175-81. PMC: 4124425. DOI: 10.3748/wjg.v12.i8.1175. View

12.

Tanaka K, Kondoh N, Shuda M, Matsubara O, Imazeki N, Ryo A . Enhanced expression of mRNAs of antisecretory factor-1, gp96, DAD1 and CDC34 in human hepatocellular carcinomas. Biochim Biophys Acta. 2001; 1536(1):1-12. DOI: 10.1016/s0925-4439(01)00026-6. View

13.

Arnoletti J, Albo D, Jhala N, Granick M, Solomon M, Atkinson B . Computer-assisted image analysis of tumor sections for a new thrombospondin receptor. Am J Surg. 1994; 168(5):433-6. DOI: 10.1016/s0002-9610(05)80093-5. View

14.

Wakiyama T, Shinohara T, Shirakusa T, John A, Tuszynski G . The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer. Histol Histopathol. 2001; 16(2):345-51. DOI: 10.14670/HH-16.345. View

15.

Nilsson L, Lange S, Lonnroth I . Induction of anti-secretory factor in mice by the nonintestinal parasite Schistosoma mansoni. J Parasitol. 1992; 78(6):1055-8. View

16.

Poon R, Chung K, Cheung S, Lau C, Tong S, Leung K . Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res. 2004; 10(12 Pt 1):4150-7. DOI: 10.1158/1078-0432.CCR-03-0435. View